Steven Cohen Vaxart, Inc. Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.69 - $0.85 $1,059 - $1,305	-1,536 Reduced 7.82%	18,118 $13,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $50,031 - $117,572	-83,385 Reduced 80.93%	19,654 $14,000
Q1 2023 May 15, 2023	BUY	$0.71 - $1.25 $73,157 - $128,798	103,039 New	103,039 $78,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.